In urothelial cancer, ICI offers an alternative approved treatment for patients who have failed on platinum-based chemotherapy, with ORRs of approximately 20% in patients with PD-L1+ tumors.30 In breast cancer, the most prominent results have been observed in PD-L1+ advanced TNBC,31-33 leading to the approval of pembrolizumab with chemotherapy for first-line treatment of these patients. This evidence concerns the gene CD274 and breast cancer.